28736-83-6

Upstream product

• 529-53-3 scutellarein 
• 1105056-24-3 9-hydroxy-6-(4-hydroxyphenyl)-2,2-diphenyl-8H-1,3-dioxolo[4,5-g][1]benzopyran-8-one 
• 1402607-40-2 9-hydroxy-2,2-diphenyl-6-[4-(phenylmethoxy)phenyl]-8H-1,3-dioxolo[4,5-g][1]benzopyran-8-one 
• 1351585-69-7 5,6,7-trihydroxy-2-[4-(phenylmethoxy)phenyl]-4H-1-benzopyran-4-one 
• 27740-01-8 scutellarin 

Downstream Products

• 1447-88-7 hispidulin 
• 6601-62-3 salvigenin 
• 520-12-7 pectolinarigenin 

Relevant academic research and scientific papers

A 6-methyl Scutellarin arctigenin method for the preparation of (by machine translation)

The invention relates to the field of chemical synthesis, in particular to Chinese traditional medicine molecule Scutellarin active metabolite of preparation, the ponicidin breviscapine under the action of the strong acid hydrolysis glucuro molecules are the 4 [...], 5, 6, 7? Four hydroxy flavone, the 4 [...], 5, 6, 7? Four hydroxy flavone with bromo the presence of the acid-binding agent, generating 5,6? Dihydroxybenzonic? 4 the [...], 7? B benzyloxy flavone, then in alkaline conditions with iodomethane reaction generating 5? Hydroxy? 6? Methoxy? 4 the [...], 7? B benzyloxy flavone, the final 5? Hydroxy? 6? Methoxy? 4 the [...], 7? B benzyloxy-flavone in palladium carbon catalytic hydrogenation by debenzylation in the presence of 6? Methyl Scutellarin aglycon. The step of this invention is simple, is easy to be purified, mild condition, low cost, overall reaction yield is greater than 70%, the synthetic product has high purity, greater than 99.0%, suitable for technical production. (by machine translation)

Synthesis and biological evaluation of methylated scutellarein analogs based on metabolic mechanism of scutellarin in vivo

Scutellarin (1) could be hydrolyzed into scutellarein (2) in vivo and then converted into methylated, sulfated and glucuronidated forms. In order to investigate the biological activities of these methylated metabolites, eight methylated analogs of scutellarein (2) were synthesized via semi-synthetic methods. The antithrombotic activities of these compounds were evaluated through the analyzation of prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT) and fibrinogen (FIB). Their antioxidant activities were assessed by measuring their scavenging capacities toward 1,1-diphenyl-2-picrylhydrazyl radical (DPPH) and the ability to protect PC12 cells against H2O2-induced cytotoxicity. Furthermore, the physicochemical properties of these compounds including aqueous solubility and lipophilicity were also investigated. The results showed that 6-O-methylscutellarein (5) demonstrated potent antithrombotic activity, stronger antioxidant activity and balanced solubility and permeability compared with scutellarin (1), which warrants further development of 5 as a promising lead for the treatment of ischemic cerebrovascular disease.

An improved synthesis of 6-o-methyl-scutellarein through selective benzylation

An improved synthesis of 6-O-methyl-scutellarein is described. Benzyl bromide was selected to protect both the hydroxyl groups at C-4'and C-7 in scutellarein. The product was then methylated and deprotected to produce the target compound in high yield in four steps.

Efficient synthesis of 6-o-methyl-scutellarein from scutellarin via selective methylation

Scutellarin (1) possesses distinguished efficacy in the clinical therapy of cerebral infarction, coronary heart disease, and angina pectoris. Scutellarin (1) is readily converted in vivo, therefore, synthetic methods for the construction of its metabolite